NCT05053152 2026-01-14
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
Phase 2 Recruiting
Clinical Trials
12 trialsNCT04158245 2025-09-22
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Tulane University
Phase 2 Completed
NCT03707184 2024-11-29
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
University of Utah
Phase 2 Completed
NCT03762759 2024-05-17
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Emory University
Phase 2 Active not recruiting
NCT03263780 2021-02-21
High Resolution PET-MRI Before Prostate Cancer HIFU
Cedars-Sinai Medical Center
Phase 2 Completed
NCT03081884 2021-01-25
EDRN-FACBC
Emory University
Phase 2 Completed
NCT03515577 2020-10-14
PSMA vs AXUMIN
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02830880 2020-01-07
FACBC Prostate Therapy Response
Emory University
Phase 2 Completed
NCT01808222 2019-01-07
FACBC for Recurrent Prostate Cancer
Emory University
Phase 2 Completed
NCT00562315 2016-06-21
FACBC PET/CT for Recurrent Prostate Cancer
Emory University
Phase 2 Completed
NCT01176513 2014-02-14
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
GE Healthcare
Phase 2 Terminated
NCT00917865 2014-01-07
FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer
Emory University
Phase 2 Terminated